SCHEMBL6997115

SCHEMBL6997115

O=S1(=O)c2ccccc2CCN1CCCCl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PER2 O15055 2/20 0.48
CRY1 Q16526 2/20 0.48
CRY2 Q49AN0 2/20 0.48
KMT2A Q03164 4/20 0.43
MDM2 Q00987 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
MEN1 O00255 3/20 0.42
SIGMAR1 Q99720 1/20 0.37
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36
DRD5 P21918 1/20 0.36
DRD3 P35462 1/20 0.36
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 2/20 0.35
ESR1 P03372 1/20 0.35
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14544862 0.78 PER2 (0.52) PER2CRY1CRY2KMT2AMDM2
SCHEMBL12601141 0.78 PER2 (0.52) PER2CRY1CRY2KMT2AMDM2
SCHEMBL6714419 0.74 PER2 (0.51) PER2CRY1CRY2KMT2AMDM2
SCHEMBL7111044 0.74 HTR7 (0.40) KMT2AMEN1DRD2DRD1DRD4
SCHEMBL8283892 0.74 PER2 (0.59) PER2CRY1CRY2KMT2AMDM2
SCHEMBL6999498 0.73 HTR1A (0.55) SIGMAR1DRD2DRD1DRD4DRD5
SCHEMBL12536870 0.72 DRD2 (0.48) PER2CRY1CRY2SIGMAR1MAOA
SCHEMBL6996892 0.72 TDP1 (0.65) KMT2AMDM2CTDSP1MEN1TDP1
SCHEMBL31643404 0.71 KMT2A (0.70) PER2CRY1CRY2KMT2AMDM2
Ethylene SCHEMBL8644556 0.70 TDP1 (0.62) KMT2AMDM2CTDSP1MEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
EP-0686632-B1 BENZOTHIAZINE DERIVATIVE DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-08-06 EP disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
CN-1281854-A Benzothiazine derivative SUNTORY LTD (JP) 2001-01-31 CN disclosed
CN-1058492-C benzothiazine derivatives SUNTORY LTD (JP) 2000-11-15 CN disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
US-5874429-A ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS SUNTORY LIMITED (JP) 1999-02-23 US disclosed
CN-1119859-A benzothiazine derivatives SUNTORY LTD (JP) 1996-04-03 CN disclosed
EP-0686632-A1 BENZOTHIAZINE DERIVATIVE SUNTORY LIMITED (JP) 1995-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 PER2 1349/4885CRY1 2423/4885CRY2 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.